Chemical Structure (Fintepla 01)
Fintepla Solution
Product Images NDC 43376-322
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 28 technical images submitted to the FDA as part of the official labeling for Fintepla (NDC 43376-322). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Ucb, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (Fintepla 02)
Figure 2 (Fintepla 03)
The text is indicating a chart or table that shows the proportion of patients and percentage reduction from baseline in convulsive seizure frequency. No further information is available from the given text.*
Figure 3 (Fintepla 04)
Ifu4 (Fintepla 05)
Description: This is a medication package that includes one bottle of FINTEPLA Oral Solution with a concentration of 2.2 mg/mL, as well as two oral syringes.*
Ifu5 (Fintepla 06)
This text is a product description for two sets of oral syringes. The first set contains two syringes with a capacity of 3mL each and dose markings in 0.1 mL increments. The second set contains two syringes with 6mL capacity each and dose markings in 0.5 mL increments. These syringes seem to be designed for measuring and administering medication orally.*
Ifu6 (Fintepla 07)
This text is describing the parts of a syringe which include the tip, barrel, base, and plunger.*
Ifu7 (Fintepla 08)
Ifu8 (Fintepla 09)
Ifu9 (Fintepla 10)
Ifu10 (Fintepla 11)
Ifu11 (Fintepla 12)
Ifu12 (Fintepla 13)
Ifu13 (Fintepla 14)
Ifu15 (Fintepla 15)
Ifu16 (Fintepla 16)
This is a description of a 3 mL syringe that has dose markings in 0.1 mL increments. The text does not provide any further information.*
Ifu17 (Fintepla 17)
This text indicates that the 6 mL syringe has dose markings in increments of 0.5 mL. It does not give any additional context or information.*
Ifu18 (Fintepla 18)
Ifu19 (Fintepla 19)
Ifu20 (Fintepla 20)
Ifu21 (Fintepla 21)
Ifu22 (Fintepla 22)
Ifu23 (Fintepla 23)
30 mL Bottle Label (Fintepla 24)
This is a medication called Fmtepla which contains fenfluramine in an oral solution. The NDC code is 43376-322-30 and each bottle contains 30mL of liquid with a concentration of 2.2 mg/mL. It is only for oral use and should be stored at a controlled room temperature between 68°F to 77°F (20°C to 25°C). The pharmacist must dispense the enclosed medication guide to each patient. The unused portion of the bottle should be discarded 3 months after first opening. The medication is recommended by Zogenix Inc. in Emeryville, CA. The recommended dosage should be consulted with the prescribing information.*
30 mL Carton Label (Fintepla 25)
This is a description of Finteplar (fenfluramine) as an oral solution with a concentration of 2.2 mg/mL. It is recommended to see the prescribing information for the dosage. The medication guide should be given to each patient, and the drug should be stored at a controlled room temperature between 68°F and 77°F (20°C to 25°C). The contents include one 30 mL bottle, and the unused portion should be discarded after 3 months from the first opening.*
360 mL Bottle Label (Fintepla 26)
This is a medication labeled with the NDC code 43376-322-36. It is an oral solution with a concentration of 2.2 mg/mL, and it is stored at controlled room temperature. The medication is only for oral use and should be used as directed, with the recommended dosage being provided in the prescribing information. The pharmacist is instructed to dispense a medication guide to each patient. The medication should not be refrigerated or frozen and any unused portion should be discarded 3 months after first opening.*
360 mL Carton Label (Fintepla 27)
Fintepla is an oral solution medication containing 2.2 mg/mL of fenfluramine and is intended for oral use. It is recommended to see the prescribing information for the recommended dosage. Each medication guide should be dispensed to patients, and the contents of one 360 ml bottle should be used. The medication should be stored at a controlled temperature of 68°F to 77°F (20°C to 25°C) and not refrigerated or frozen. The unused portion should be discarded within three months after the first opening, as stated in the NDC 43376-322-36.*
Fintepla 28
The document appears to be a graph representing the percentage reduction from baseline in drop seizure frequency in patients. The graph compares the effects of three different drugs: placebo, BFINTEPLA 0.2 mg/kg/day, and WFINTEPLA 0.7 mg/kg/day. The x-axis of the graph represents the different percentage ranges of reduction, while the y-axis represents the different drugs. It appears that both BFINTEPLA and WFINTEPLA have a significantly greater effect on reducing drop seizure frequency than placebo.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
